Lung cancer with a rare kidney inflammation, successfully treated with steroids and radiation
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- EGFR mutation-negative; TTF-1-positive; CK7-positive; CK20-negative
- Sex
- Male
- Treatment
- radiation and supportive care
- Outcome
- Responding Well
Treatment course, step by step
- Prednisolone 40 mg daily, tapered by 5-10 mg every 4-8 weeks, treated ANCA-negative crescentic glomerulonephritis.
- Lung cancer received 60 Gy radiation to the mediastinal lesion because chemotherapy was unsuitable with renal dysfunction.
What happened, in summary
A 63-year-old man was admitted after 3 months of repeated high fevers. He also developed small areas of redness on his face and limbs. Chest imaging found several enlarged lymph nodes in the mediastinum, although no clear primary mass was visible in the lungs. Bronchoscopic biopsy of a lymph node showed metastatic adenocarcinoma. The cells were positive for TTF-1 and CK7 and negative for CK20, supporting a lung origin. EGFR mutation testing was negative.
During the same evaluation, his kidney function worsened quickly. Creatinine rose from 0.56 to 3.59 mg/dL within weeks, and urine protein reached 9.21 g/gCr. Kidney biopsy showed severe crescentic inflammation without ANCA antibodies, consistent with ANCA-negative pauci-immune glomerulonephritis.
Prednisolone 40 mg daily was started and then gradually reduced over several months. The fever, swelling, kidney function, and urinary protein all improved. Because the kidney injury made standard chemotherapy difficult, the lung cancer was treated with 60 Gy of radiation directed at the mediastinal disease.
The enlarged cancerous nodes shrank significantly after radiation. He was followed without evidence of renewed kidney inflammation. Five years after discharge, he remained alive without progression of the lung cancer or kidney disease. His course showed long-term control using radiation for the cancer and corticosteroids for the associated kidney problem.
The absence of a visible lung mass made the diagnosis less straightforward, but the lymph-node markers supported a lung primary. Long follow-up showed durable control without chemotherapy.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Metastatic Lung Cancer 25 stories
- Radiation for Lung Cancer 242 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer